Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFN-γ) in type 1 diabetes mellitus nephropathy
@inproceedings{Ellina2012ExtracellularM, title={Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFN-$\gamma$) in type 1 diabetes mellitus nephropathy}, author={Olga Ellina and Antonios Chatzigeorgiou and Sophia Kouyanou and Maria Lymberi and Christina Mylona-Karagianni and Emmanouil Tsouvalas and Elli F. Kamper}, booktitle={Clinical chemistry and laboratory medicine}, year={2012} }
Abstract Background: The aim of the present study was to evaluate the role of extracellular matrix-associated glycosaminoglycans (GAGs), connective tissue growth factor (CTGF), angiogenic vascular endothelial growth factor (VEGF) and inflammatory factors (MCP-1, CD40, IFN-γ) in the development of diabetic nephropathy in type 1 diabetes (T1DM). Methods: Plasma and urine samples from 30 T1DM patients and 20 healthy controls were used to measure the levels of CTGF, VEGF, MCP-1, CD40 and IFN-γ by…
18 Citations
Role of immune dysfunction in pathogenesis of type 1 diabetes mellitus in children.
- Biology, MedicineAsian Pacific journal of tropical medicine
- 2014
Polymporphism of monocyte chemoattractant protein 1 (MCP1 -2518 A/G) and responsiveness to hepatitis B vaccination in hemodialysis patients.
- Medicine, BiologyPolskie Archiwum Medycyny Wewnetrznej
- 2014
MCP10-2518 A/G polymorphism is not associated with responsiveness to hepatitis B vaccination in patients on hemodialysis, independently of whether they have diabetes or not.
Correlation Between Serum miR-154-5p and Osteocalcin in Males and Postmenopausal Females of Type 2 Diabetes With Different Urinary Albumin Creatinine Ratios
- Medicine, BiologyFront. Endocrinol.
- 2019
It is suggested that increased serum levels of miR-154-5p and decreased OC levels may influence osteogenesis and proteinuria in T2DM and may identify novel targets for diagnosis and treatment of diabetic kidney disease and osteoporosis.
Chemokines in Type 1 Diabetes Mellitus
- Medicine, BiologyFrontiers in Immunology
- 2021
Background Previous studies suggested that chemokines may play an important role in the formation and mediation of immune microenvironments of patients affected by Type 1 Diabetes Mellitus (T1DM).…
miR-154-5p Affects the TGFβ1/Smad3 Pathway on the Fibrosis of Diabetic Kidney Disease via Binding E3 Ubiquitin Ligase Smurf1
- Biology, ChemistryOxidative medicine and cellular longevity
- 2022
Aim The study is aimed at verifying miR-154-5p and Smurf1 combination in glomerular mesangial cells regulating TGFβ1/Smad3 pathway-related protein ubiquitination in the model of diabetic rats renal…
Connective tissue growth factor expression hints at aggressive nature of colorectal cancer
- MedicineWorld journal of gastroenterology
- 2022
expression of CTGF was increased in CRC and was linked with poor overall and disease-free survival of CRC patients, which support prior observations and thus CTGF may be a possible prognostic marker in CRC.
Oxidative stress is responsible for maternal diabetes-impaired transforming growth factor beta signaling in the developing mouse heart.
- Medicine, BiologyAmerican journal of obstetrics and gynecology
- 2015
Connective Tissue Growth Factor Transgenic Mouse Develops Cardiac Hypertrophy, Lean Body Mass and Alopecia.
- BiologyJournal of clinical and diagnostic research : JCDR
- 2017
It is shown that CTGF transgenic mouse has cardiac and aorta root hypertrophy and abnormal renin accumulation in aortA root as compared to the wild-type animals and may be involved in vascular tone control.
The serum levels of connective tissue growth factor in patients with systemic lupus erythematosus and lupus nephritis
- Medicine, BiologyLupus
- 2014
The expression of connective tissue growth factor mRNA in human kidneys may serve as an early marker for lupus nephritis progression and be involved in the pathogenesis of systemic l upus erythematosus and lupu nephitis.
Esculin ameliorates cognitive impairment in experimental diabetic nephropathy and induces anti-oxidative stress and anti-inflammatory effects via the MAPK pathway.
- Biology, ChemistryMolecular medicine reports
- 2018
Results indicate that esculin may ameliorate cognitive impairment in experimental DN, and exert anti‑oxidative stress and anti‑inflammatory effects, via the MAPK signaling pathway.
References
SHOWING 1-10 OF 53 REFERENCES
Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy.
- MedicineCytokine
- 2009
Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss.
- Medicine, BiologyKidney international
- 2007
The results may suggest that downregulation of VEGF-A and CTGF in DN is a result of podocyte loss, and an inverse correlation between podocin message and the extent of interstitial fibrosis.
The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time
- Biology, MedicineAnnals of medicine
- 2010
A parallel elevation of both inflammatory and anti-inflammatory cytokines was observed in patients compared with HCs, suggesting a possible role of Th1 cells in the progress of beta-cell destruction during the first period of the disease.
Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy.
- MedicineDiabetes care
- 2006
The observed association of U-CTGF with UAE and glomerular filtration rate might reflect a role of CTGF as progression promoter in diabetic nephropathy.
Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes.
- MedicineDiabetes care
- 2002
Long-term treatment of high-dose vitamin E significantly decreased MCP-1, thus providing a rationale basis for evaluating vitamin E supplementation as therapy adjuvant to conventional insulin treatment in type 1 diabetic patients in whom an acceptable glycemic control is difficult to achieve despite appropriate insulin treatment.
Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy.
- MedicineKidney international. Supplement
- 2000
The data suggest that VEGF is elevated early in the course of diabetic nephropathy in men with type 1 diabetes mellitus, and the following baseline variables acted as predictors of progression: albuminuria, mean arterial blood pressure and male gender.
Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?
- Biology, MedicineJournal of Cell Communication and Signaling
- 2009
Examination of changes in CTGF expression in the kidney in DN, the effects they have on glomerular mesangial and podocyte cells and the tubulointerstitium, and how these contribute to driving fibrotic changes in the disease are examined.
CD40 expression and its association with low-grade inflammation in a Greek population of type 1 diabetic juveniles: evidence for differences in CD40 mRNA isoforms expressed by peripheral blood mononuclear cells.
- Medicine, BiologyExperimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
- 2010
Homeostatic dysregulation of CD40 and its association with inflammatory markers in T1DM patients, especially in those with poor glycaemic control, implies a pathophysiological role ofCD40 in the low-grade inflammatory process in T 1DM.
Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus.
- Medicine, BiologyCurrent drug targets
- 2011
Inhibition of VEGF in experimental DN ameliorates structural and functional changes and proposes possible therapeutic targets in diabetic patients at early stages of DN.
Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy.
- Medicine, BiologyClinica chimica acta; international journal of clinical chemistry
- 2010